VR Logo

GH Research PLC (GHRS) download report


Healthcare | Biotechnology & Pharma Research

GH Research PLC (GHRS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders.

IPO Date: 25-Jun-2021

Co-Founder & Non-Exec. Chairman: Mr. Florian Schonharting M.Sc. (Econ)

Co-Founder & CEO: Mr. Theis Terwey M.D.

Listing: NASDAQ: GHRS

Country: Ireland

Headquarters: Dublin,

Website: https://www.ghres.com

Key Facts

Market cap: $572.23 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-13.82 Mln

Cash: $270.75 Mln

Total Debt: $0.00 Mln

Insider's Holding: 41.32%

Liquidity: Low

52 Week range: $8.72 - 30.43

Shares outstanding: 52,020,800

Stock Performance

Time Period GH Research (GHRS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-52.85-8.74-17.60
1 month12.94-2.01-5.38
3 months-35.71-7.32-13.22
1 Year--0.45-16.83
3 Years--10.327.77
5 Years--11.296.21
10 Years--12.1410.48
As on 24-Jun-2022 *As on 27-Jun-2022